secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPLASH BEVERAGE GROUP, INC. (SBEV)
CIK:        0001553788
Form:       8-K
Filed at:   2026-08-04T20:30:34+00:00
Accession:  0001731122-26-001012
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Splash Beverage enters development collaboration with Lupvindol for veterinary drug from CannEpil
--------------------------------------------------------------------------------

- Lupvindol to lead FDA INAD and conditional approval for CannEpil-based veterinary product in companion-animal oncology and pain.
- Milestone payments total up to $1.11M plus 4% royalty on net sales (or equity election) upon conditional approval or earlier licensing.
- Splash provides milestone funding and commercial support; Lupvindol handles development and regulatory activities.
- Initial term 5 years, auto-renew; Splash can terminate for convenience with 90 days notice and wind-down fee equal to next milestone.
- Collaboration follows July 2026 exclusive license from Argent Biopharma (RGT) for CannEpil; royalty to RGT is 10% of net revenue for veterinary use.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553788/000173112226001012/0001731122-26-001012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553788/000173112226001012/e7825_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-001012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer